PHOTO FILE: CEO Vas Narasimhan of Swiss drugmaker Novel, Switzerland January 30, 2019. REUTERS / Arnd Wiegmann
ZURICH (Reuters) – Novartis could be a big business business. T “a little sooner” until 2022, as it now forecasts,
35%, ”They said to her. event. “That could happen a little sooner, we see it on how the launches go. If they did (better launch), I think we would get there sooner.
The first year of the year, from 31.3% of sales, from 31.3% of sales, from 31.3% of sales
Reporting by John Miller; Editing by Michael Shields
(tagsToTranslate) US (t) NOVARTIS (t) INVESTORS (t) MARGIN (t) Results Forecasts / Warnings (t) Mergers / Acquisitions / Takeovers (t) Switzerland (t) China (PRC) (t) Pharmaceuticals (TRBC) (t) Asia / Pacific (t) Europe (t) Pharmaceuticals and Medical Research (TRBC) (t) Healthcare (TRBC)